AquaHeart Technology - helping Patients suffering from atrial Fibrillation

  • Atrial fibrillation is a rhythm disorder, predominantly in the elderly population, which goes along with a loss of performance and a significantly elevated risk of cerebral stroke
  • The established therapies in the Cardiology world are either anti-arrhythmic drugs or catheter ablation
  • Recent studies have demonstrated that ablation should be the frontline therapy (guidelines pending)
  • Ablation therapy in first place is the electrical insulation of the so-called pulmonary veins in the left atrium

The AquaHeart system allows for a so called „single shot“, ultra short insulation of each of the pulmonary veins. 

Democratizing Heart Ablation for a Larger Population

Atrial Fibrillation is a potentially deadly condition, yet only 10% of patients receive curative treatment today. At AquaHeart, we are on a mission to change that. Our groundbreaking high-energy, short-duration, single-shot Pulmonary Vein Isolation technology is paving the way for accessible treatment on a global scale.

By developing a solution that can be applied faster, safer, and more easily, we are addressing a large unmet need of untreated Atrial Fibrillation patients. With AquaHeart, heart ablation is no longer limited to a select few—it is now within reach for all patients and interventional cardiologist.

Recognized as a Top 10 Cardiovascular Solution Provider 2023

April 2023, AquaHeart was honored to be listed as a top 10 solution provider in the cardiovascular space. Our CEO, Dr. Holger Friedrich, highlighted the remarkable benefits of the AquaHeart system in an article, solidifying our position as leaders in the field of Pulmonary Vein Isolation. We are proud to be driving advancements that will reshape the landscape of cardiac care.